#Aim stocktwits update#

#Aim stocktwits update#

Wainwright Global Investment ConferenceĪIM working on new drug application for Ampligen mid-stage study to treat long COVIDĪIM ImmunoTech Provides Update on Ampligen Long COVID Development ProgramĪIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate UpdateĪIM ImmunoTech to Participate in a Solve M.E. We have 9 different ratings for every stock to help you appreciate its future potential. Keywords: Medicine Cancer Disease Acid Infectious Diseases Health Care Melanoma Pancreatic Cancer Carcinoma Hepatitis B HIV Renal Cell Carcinoma Interferon Treatment Of Hepatitis Fatigue Treatment Of Hepatitis B Genital WartĪIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and TestingĪIM ImmunoTech receives patent coverage in Netherlands for potential COVID-19 treatmentĪIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or PreventionĪIM ImmunoTech to Present at the H.C. Home > Parliamentary Proceedings > Bills > Bill 102, An Act to amend the Environment Quality Act to modernize the environmental authorization scheme and to. was founded in 1966 and is headquartered in Ocala, Florida. and changed its name to AIM ImmunoTech Inc. The aim of this content is to help readers understand the bands better as well as introduce them to how they. AIMs flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. The company was formerly known as Hemispherx Biopharma, Inc. AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd.

Share your opinion and gain insight from other stock traders and. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. (AIM) stock discussion in Yahoo Finances forum.

The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States.